Jon M. Richards
Advocate Health Care · 95 works · 13,885 citations · h-index 36
Top works
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
- Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
- Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group
- Implications of Microscopic Satellites of the Primary and Extracapsular Lymph Node Spread in Patients With High-Risk Melanoma: Pathologic Corollary of Eastern Cooperative Oncology Group Trial E1690
- Effective chemotherapy for melanoma after treatment with interleukin-2
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic Melanoma
- Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
- Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results.
- Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
- An IgG‐Fc Binding Protein in Seminal Fluid*
- Sequential Chemoimmunotherapy in the Treatment of Metastatic Melanoma
- Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies.